1.Geyer, HL, Bressman, SB.The diagnosis of dystonia. Lancet Neurol. 2006; 5(9):780–90.
2.Auger, RG, Whisnant, JP.Hemifacial spasm in Rochester and Olmsted County, Minnesota, 1960 to 1984. Arch Neurol. 1990; 47(11):1233–4.
3.Claypool, DW, Duane, DD, Ilstrup, DM, Melton, LJ III. Epidemiology and outcome of cervical dystonia (spasmodic torticollis) in Rochester, Minnesota. Mov Disord. 1995; 10(5):608–14.
4.Nakashima, K, Kusumi, M, Inoue, Y, Takahashi, K.Prevalence of focal dystonias in the western area of Tottori Prefecture in Japan. Mov Disord. 1995; 10(4):440–3.
5.A prevalence study of primary dystonia in eight European countries. J Neurol. 2000; 247(10):787–92.
6.Marras, C, Van den Eeden, SK, Fross, RD, et al.Minimum incidence of primary cervical dystonia in a multiethnic health care population. Neurology. 2007; 69(7):676–80.
7.Nutt, JG, Muenter, MD, Aronson, A, Kurland, LT, Melton, LJ III. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord. 1988; 3(3):188–94.
8.Defazio, G, Livrea, P, De Salvia, R, et al.Prevalence of primary blepharospasm in a community of Puglia region, Southern Italy. Neurology. 2001; 56(11):1579–81.
9.Cossu, G, Mereu, A, Deriu, M, et al.Prevalence of primary blepharospasm in Sardinia, Italy: a service-based survey. Mov Disord. 2006; 21(11):2005–8.
10.Hallett, M.Blepharospasm: recent advances. Neurology. 2002; 59(9):1306–12.
11.Jankovic, J, Tsui, J, Bergeron, C.Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007; 13(7):411–16.
12.Jankovic, J.Treatment of hyperkinetic movement disorders. Lancet Neurol. 2009; 8(9):844–56.
13.Simpson, DM, Blitzer, A, Brashear, AM, et al.Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008; 70(19):1699–706.
14.Albanese, A.The clinical expression of primary dystonia. J Neurol. 2003; 250(10):1145–51.
15.Abdo, WF, van de Warrenburg, BP, Burn, DJ, Quinn, NP, Bloem, BR.The clinical approach to movement disorders. Nat Rev Neurol. 2010; 6(1):29–37.
16.Swope, D, Barbano, R.Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia. Neurol Clin. 2008; 26 Suppl 1:54–65.
17.Kenney, C, Jankovic, J.Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm. 2008; 115(4):585–91.
18.Hallett, M, Evinger, C, Jankovic, J, Stacy, M.Update on blepharospasm: report from the BEBRF InternationalWorkshop. Neurology. 2008; 71(16):1275–82.
19.Albanese, A, Lalli, S.Is this dystonia? Mov Disord. 2009; 24(12):1725–31.
20.Hilker, R, Schischniaschvili, M, Ghaemi, M, Jacobs, A, Rudolf, J.Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry. 2001; 71(2):193–9.